Amphastar Pharmaceuticals, Inc. Share Buyback Program Increase

Amphastar Pharmaceuticals, Inc. announced on March 12, 2026, that its Board of Directors has authorized an increase of $50 million to the company's existing share buyback program. This program, which is intended to offset dilution from equity compensation plans, will continue for an indefinite period. Share repurchases may be executed through various methods, including open market transactions, private block trades, and privately negotiated deals, all in compliance with SEC regulations and applicable laws. The specific timing and volume of share repurchases will be influenced by factors such as stock price, corporate needs, and regulatory conditions.